What conditions can fibrotic hypersensitivity pneumonitis be misdiagnosed as?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What Fibrotic Hypersensitivity Pneumonitis Is Commonly Misdiagnosed As

Fibrotic hypersensitivity pneumonitis (fHP) is most commonly misdiagnosed as idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), and less frequently as fibrotic nonspecific interstitial pneumonia (NSIP). 1, 2, 3

Primary Diagnostic Confusion: IPF/UIP

The most critical misdiagnosis is confusing fHP with IPF, which has profound treatment implications since:

  • IPF requires antifibrotic agents (nintedanib, pirfenidone)
  • fHP requires antigen avoidance and immunosuppressive therapy 1
  • Immunosuppression is harmful in IPF and should be avoided 1
  • fHP patients have significantly better survival after lung transplantation compared to IPF patients 3

Why This Confusion Occurs

Both conditions share multiple overlapping features 1:

  • Dyspnea and chronic cough
  • Inspiratory crackles on examination
  • Restrictive physiology on pulmonary function testing
  • Gastroesophageal reflux disease
  • Family history of ILD (increasingly recognized in fHP)

On HRCT imaging, fHP can produce a UIP-like pattern that mimics IPF 2, 3, 4. Approximately 50% of cases cannot be separated radiologically 3.

On surgical lung biopsy, fHP frequently shows UIP-like fibrosis with patchy subpleural fibrosis, fibroblastic foci, and even honeycomb changes 2, 3.

Secondary Misdiagnosis: Fibrotic NSIP

fHP can also present with an NSIP-like pattern showing 2:

  • Expanded alveolar septa with fibrous tissue
  • Relative preservation of alveolar architecture
  • Lymphocytic infiltrates in alveolar septa

Other Conditions in the Differential

Less commonly, fHP may be misdiagnosed as 5, 6:

  • Recurrent pneumonia (particularly in acute/subacute presentations)
  • Asthma (when airway involvement causes obstructive features)
  • Hamman-Rich disease (acute interstitial pneumonitis)
  • Nonspecific interstitial pneumonitis

Key Distinguishing Features to Prevent Misdiagnosis

Clinical Profile Differences 1

Classic IPF profile:

  • Male sex
  • Age >60 years
  • Cigarette smoking history
  • Lower lobe predominance

Classic fHP profile:

  • Any age (typically younger than IPF patients) 2, 3
  • Equal sex distribution 1
  • Identifiable antigen exposure (birds, molds) that temporally parallels disease 1, 7
  • Inspiratory squawks 1

HRCT Distinguishing Features 3, 8, 4

Features favoring fHP over IPF:

  • Upper and middle lobe predominance (vs. lower lobe in IPF) 2
  • Mosaic attenuation/air-trapping 2, 4
  • Centrilobular nodules (highly specific for fHP) 3, 4
  • Diffuse craniocaudal distribution rather than basilar 4
  • Less honeycombing compared to IPF 4

Pathologic Distinguishing Features 3

Features favoring fHP:

  • Peribronchiolar (centrilobular) fibrosis - isolated foci frequently associated with fibroblast foci
  • "Bridging fibrosis" - fibrosis extending from centrilobular region to another bronchiole, interlobular septum, or pleura (uncommon in IPF)
  • Bronchiolar metaplasia of peribronchiolar alveoli
  • Mild bronchiolitis

Important caveat: Giant cells and granulomas are typically present in subacute HP but are much less frequently found in chronic/fibrotic HP, and their absence does not exclude the diagnosis 3.

Critical Diagnostic Algorithm

Per current guidelines 1, 7:

  1. Thorough exposure history - use structured questionnaire to identify bird, mold, or other antigen exposures
  2. Serum IgG testing against potential HP antigens 7
  3. HRCT with attention to distribution and specific patterns 7, 8
  4. BAL with lymphocyte cellular analysis (recommended for both nonfibrotic and fibrotic HP) 7
  5. Multidisciplinary discussion integrating clinical, radiologic, and pathologic data 1, 7
  6. Consider transbronchial cryobiopsy or surgical lung biopsy when diagnosis remains uncertain 7

Common Pitfalls

  • Assuming absence of granulomas excludes fHP (they are uncommon in chronic/fibrotic disease) 3
  • Failing to obtain detailed environmental exposure history 1, 7
  • Relying solely on radiologic UIP pattern without considering clinical context 1
  • Not recognizing that fHP can have similar progression rates to IPF 1
  • Missing the therapeutic window - antigen avoidance improves outcomes but only if implemented early 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.